MedTrace Logo

Cohort of IPF Patients Experiencing an Exacerbation

NCT04442711 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-12-22

No results posted yet for this study

Summary

Extension of the PFBIO cohort which includes patients with newly diagnosed idiopathic pulmonary fibrosis (IPF) for longitudinal follow-up for up to 5 years.

In the PFBIO-EXA extension, patients are included if they experience an exacerbation, or other increase in respiratory symptoms requiring hospital admission, for further collection of clinical and biological data.

Conditions

Sponsors & Collaborators

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-13
Primary Completion
2027-12-01
Completion
2028-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04442711 on ClinicalTrials.gov